BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
fund-news - VC Tracker Resources
Discover comprehensive resources and guides related to fund-news. Our comprehensive guides cover VC analysis preparation, investment resources, and practical advice for investors and analysts.
Whether you're an investor preparing for market analysis, a portfolio manager helping with investment tracking, or an analyst looking for resources, you'll find valuable insights in the articles below.
Related Articles (12 articles)
Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
Blackstone's $10B Capital Opportunities V: Private Credit Reshapes the VC Exit Path
Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.
KKR's $23B North America PE Fund: Scale Capital Reshapes the Growth-Stage VC Market
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.
Lumen II's €100M Seed Fund: Sector Specialism Returns to European Seed
Lumen II's new €100M vehicle for seed-stage fintech, insurtech, digital health, and cybersecurity is a rare large EU sector-specific seed fund.
NVCA 2026 Yearbook: A Venture Industry in Transition — Fewer Funds, Bigger Winners
NVCA's 2026 Yearbook shows $67B raised across 585 U.S. funds in 2025, with the top 10 funds capturing a disproportionate share — a clear structural shift.